Amoxicillin and Metronidazole During Periodontal Treatment

NCT02954393 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2020-01-13

No results posted yet for this study

Summary

The aim of this multicenter randomized clinical trial is to compare the clinical, microbiological and immunological effects of the adjunctive use of systemic metronidazole plus amoxicillin administered in different phases of the treatment of generalized chronic periodontitis.

Conditions

  • Chronic Periodontitis

Interventions

PROCEDURE

Scaling and root planing

SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.

DRUG

Metronidazole active phase

Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).

DRUG

Metronidazole healing phase

Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).

DRUG

Amoxicillin active phase

Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).

DRUG

Amoxicillin healing phase

Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).

DRUG

Placebos active phase

Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).

DRUG

Placebos healing phase

Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).

Sponsors & Collaborators

  • Belén Retamal-Valdes

    lead OTHER

Principal Investigators

  • Magda Feres, Professor · University of Guarulhos

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2019-12-31
Completion
2020-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02954393 on ClinicalTrials.gov